Cue Biopharma, Inc.
CUE
$0.84
$0.02182.66%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.14% | -75.48% | -13.45% | 58.86% | 92.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.14% | -75.48% | -13.45% | 58.86% | 92.33% |
| Cost of Revenue | -17.00% | -17.77% | -27.46% | -5.49% | -10.52% |
| Gross Profit | 27.88% | 4.70% | 29.64% | 25.15% | 25.85% |
| SG&A Expenses | 4.78% | -0.26% | -29.27% | -17.12% | -17.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.13% | -11.57% | -27.69% | -9.40% | -12.47% |
| Operating Income | 16.84% | 2.91% | 29.59% | 21.95% | 23.19% |
| Income Before Tax | 16.61% | 0.73% | 29.31% | 21.31% | 22.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.61% | 0.73% | 29.31% | 21.31% | 22.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.61% | 0.73% | 29.31% | 21.31% | 22.86% |
| EBIT | 16.84% | 2.91% | 29.59% | 21.95% | 23.19% |
| EBITDA | 17.00% | 2.95% | 29.72% | 21.95% | 23.14% |
| EPS Basic | 56.14% | 33.85% | 55.06% | 28.81% | 31.12% |
| Normalized Basic EPS | 56.20% | 33.85% | 54.55% | 28.03% | 31.10% |
| EPS Diluted | 56.14% | 33.85% | 55.06% | 28.81% | 31.12% |
| Normalized Diluted EPS | 56.20% | 33.85% | 54.55% | 28.03% | 31.10% |
| Average Basic Shares Outstanding | 90.25% | 50.11% | 57.30% | 10.51% | 12.00% |
| Average Diluted Shares Outstanding | 90.25% | 50.11% | 57.30% | 10.51% | 12.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |